Ipsen Pharma competitive analysis

Explore patent oppositions filed by Ipsen Pharma against competitors, revealing strategic technology disputes and market positioning.

Last updated on: Sep 3, 2026
Patent NumberTitleApplicantOpposition Date
Stabilized Non-Protein Clostridial Toxin CompositionsALLERGANMay 12, 2020
Stabilized Non-Protein Clostridial Toxin CompositionsALLERGANMay 12, 2020
Lyophilized Preparation Of Botulinum ToxinMEDY TOXFeb 2, 2018
Cell-Based Fluorescence Resonance Energy Transfer (Fret) Assays For Clostridial ToxinsALLERGANMay 3, 2017
Clostridial Toxin Pharmaceutical CompositionsALLERGANJan 18, 2017
Non-Protein Stabilized Clostridial Toxin Pharmaceutical CompositionsALLERGANJan 5, 2017
Preparation Containing Highly Purified Botulinum Toxin Type A Derived From Infant Botulism PathogenJURIDICAL FOUNDATIONNov 24, 2015
Immuno-Based Botulinum Toxin Serotype A Activity AssaysALLERGANJun 2, 2015

Explore Ipsen Pharma's recently opposed patents, revealing key competitive challenges and strategic patent disputes in the industry. Track oppositions filed by competitors to understand technology battlegrounds and assess potential risks.

Last updated on: Sep 3, 2026
Patent NumberPublication DateTitleTotal Oppositions
May 17, 2017A Stable Composition Comprising Pthrp And Uses Thereof3
Apr 12, 2017Novel Method For Preparing Extracts Of Ginkgo Biloba1

Latest PTAB cases involving Ipsen Pharma

Discover the latest PTAB cases involving Ipsen Pharma, highlighting their recent legal challenges and patent disputes.

Peer Comparison New

IP litigation analysis comparing Ipsen Pharma with top 3 competitors. Includes complete PTAB case data and opposition data from 2018 onwards.

Last updated on: Sep 3, 2026
CompanyOppositions FiledOppositions FacedPTAB Cases FiledPTAB Cases Faced
IPSEN PHARMA83 - -
ALLERGAN16431333
DR WILLMAR SCHWABE35 - -
ISENBRUCK BÖSL HÖRSCHLER LLP3 - - -